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H ereditary hemorrhagic telangiectasia (HHT) (Osler-Weber-Rendu disease) is an autosomal 
dominant genetic disorder characterized by multiple 
arteriovenous malformations (AVMs).  The common 
manifestations of this disease are frequent epistaxis,  
mucocutaneous telangiectasia on typical locations (lips,  
oral mucosa,  and hands),  and visceral AVM in the gas-
trointestinal tract,  liver,  lung,  and/or central nervous 
system [1 , 2].  Frequent and recalcitrant bleeding from 
the nose or mucocutaneous lesions can worsen the 
patients’ quality of life,  and major bleeding from a vis-
ceral AVM is sometimes lethal.  It is thus very import-
ant to diagnose HHT at the earliest possible time point.
Four genes (ENG,  ACVRL1,  SMAD4,  and GDF2) 
have been identified as pathogenic in HHT [3].  Among 
these,  the mutation of the 2 major genes,  ENG and 
ACVRL1,  account for about 80% of all HHT cases 
[3 , 4].  HHT type 1 (OMIM #187300) is associated with 
a mutation of ENG with a chromosomal location of 
9q34.11.  ENG encodes endoglin,  which is a component 
protein of the transforming growth factor beta (TGF-β) 
receptor complex [5-7].  HHT type 2 (OMIM #600736) 
is associated with ACVRL1 (ALK1) mutation,  which is 
located in 12q13.13.  ACVRL1 encodes a serine/thre-
onine-protein kinase receptor R3,  i.e.,  ACVRL1,  which 
is also known as activin A receptor-like kinase 1 (ALK1).  
ACVRL1 protein acts as a cell-surface receptor for the 
TGF-β signaling pathway [6 , 7].  Herein,  we describe a 
case of possible HHT in which a novel missense muta-
tion of ACVRL1 without mutation in ENG was detected.
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Hereditary hemorrhagic telangiectasia (HHT; also known as Osler-Weber-Rendu disease) is an autosomal 
dominant genetic disorder that causes frequent epistaxis,  mucocutaneous telangiectasia,  and visceral arterio-
venous malformations.  Four genes (ENG,  ACVRL1,  SMAD4,  and GDF2) have been identified as pathogenic in 
HHT.  We describe the case of a 50-year-old Japanese man highly suspected of having HHT due to recurrent 
epistaxis,  mucocutaneous telangiectasia,  and a family history.  Genomic analysis revealed a novel missense 
mutation of c.100T>A,  p.Cys34Ser in the patient’s ACVRL1 gene.  We used 6 freeware programs to perform an 
in silico analysis of this mutation.  The results demonstrated the mutation’s high pathogenicity.
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Case Report
A 50-year-old Japanese man (III-1 in Fig. 1) visited 
our hospital due to spontaneous and recurrent epistaxis.  
He had experienced epistaxis since childhood.  Over the 
3 years prior to his admission,  the frequency of the 
patient’s epistaxis increased to almost daily occurrences 
upon waking and at night.  On visual inspection,  the 
patient exhibited multiple red or pink spots reflecting 
telangiectasias on the lips,  tongue,  and palate (Fig. 2).  
Whole-body computed tomography,  magnetic reso-
nance imaging of the brain,  and abdominal echography 
did not show any visceral AVM.  The laboratory results 
were as follows: white blood cell count,  5,600/µL; red 
blood cell count,  4,760,000/µL; hemoglobin concen-
tration,  14.4 g/dL; platelet count,  253,000/µL; pro-
thrombin time (international normalized ratio),  0.90;  
and activated partial thromboplastin time,  32.0 sec.  
These findings indicated that there was no anemia or 
thrombocytopenia,  or any coagulation system disorder.
The patient’s father (II-1 in Fig. 1) and brother (III-2 
in Fig. 1) also had frequent epistaxis.  His father had 
undergone a surgical operation for recalcitrant gastric 
bleeding twice.  The patient had no spouse or children.  
It was not clear whether his grandfathers and grand-
mothers had symptoms of HHT (Fig. 1).  Based on these 
findings,  the patient was suspected of having possible 
HHT in accordance with Curaçao’s diagnostic criteria 
[8].
Blood samples were collected from the patient after 
genetic counseling by a clinical geneticist.  Written 
informed consent was obtained prior to the sample col-
lections,  which were analyzed and used for the publica-
tion of this case report.  Both the genetic testing and 
overall study protocol were approved by the Ethics 
Committee of Nihon University School of Medicine 
(nos. 149-0 and 149-1).  Genomic DNA was isolated 
from the patient’s peripheral blood lymphocytes using 
an established procedure.  Unfortunately,  the patient’s 
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Fig. 1　 The pedigree of the patientʼs family.  The proband patient 
is indicated by a black-filled square and arrow.  Squares denote 
men and circles represent women.  The patientʼs father also had 
frequent epistaxis and underwent 2 surgeries due to recalcitrant 
gastric bleeding,  and the patientʼs brother had epistaxis.  Although 
the father and brother were suspected to have HHT,  they could not 
be diagnosed with HHT due to insufficient clinical information.
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Fig. 2　 Typical images of the patientʼs telangiectasias.  A,  Some large or small red spots were observed on the lips; B,  A red spot was 
also observed on the tongue (yellow arrow); C,  Several small red or pink spots were observed on the palate.
father,  mother,  and brother lived far away,  and they did 
not agree to undergo the genetic testing.
Entire coding exons of ENG and ACVRL1,  which 
included intronic boundaries of the genes,  were ampli-
fied by polymerase chain reaction using established 
protocols.  The amplicons were examined using the 
direct sequencing apparatus of Sanger’s method (3130 
DNA Analyzer; Thermo Fisher Scientific,  Waltham,  
MA).  Sequence data were processed using the 
GeneMapperTM ID-X software ver. 1.3 and mapped to 
the human genome sequence.
The analysis of the ENG gene revealed the presence 
of a wild-type sequence in all exons.  The ACVRL1 gene 
exhibited a novel heterozygous mutation (c.100T>A) in 
exon 3,  indicating an amino acid substitution of 
p.Cys34Ser (Fig. 3).  There were no other mutations 
detected in other exons.
To predict the pathogenicity of the p.Cys34Ser mis-
sense mutation,  we performed an in silico analysis using 
6 software programs.  During the first part of the analy-
sis,  MutationTaster (http://www.mutationtaster.org/;  
accessed July 4,  2018),  SIFT (http://sift.jcvi.org/; ac-
cessed July 4,  2018),  PROVEAN (http://provean.jcvi.
org/index.php; accessed July 4,  2018),  Align GVGD 
(http://agvgd.hci.utah.edu/; accessed July 4,  2018),  
and PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/; accessed July 4,  2018) were used to evaluate the 
mutation as “disease causing,” “damaging,” “deleteri-
ous,” “most likely deleterious,” and “probably damag-
ing,” respectively,  as these could be used to demon-
strate the high pathogenicity of the mutation.  In 
addition,  the PANTHER-PSEP program (http://www.
pantherdb.org/; accessed July 5,  2018),  which uses an 
algorithm to calculate the length of time a given amino 
acid has been preserved in the evolutionary lineage,  
showed that the Cys34 amino acid residue was highly 
preserved for a period of 1,037 million years (Table 1).
Discussion
We identified a novel ACVRL1 mutation (c.100T>A,  
p.Cys34Ser) in a Japanese patient with possible HHT.  
To the best of our knowledge,  there have been no 
reports that have identified the missense mutation of 
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Fig. 3　 Direct sequencing of the ACVRL1 gene using Sangerʼs method showed an overlapping of thymine and adenine in the codon 
residue no. 100,  which indicated a heterozygous mutation of c.100T and c.100T>A.
Table 1　 In silico analysis of Cys34 residue using 6 type of software
Mutation
Algorithm
MutationTaster SIFT PROVEAN Align GVGD PolyPhen-2 PANTHER-PSEP
C.100T>A,  p.Cys34Ser
(present case)
Disease causing
(Score: 0.999999995)
Damaging
(Score: 0.00)
Deleterious
(Score: -6.430)
Most likely deleterious
(Class C65,  Score: 111.67)
Probably damaging
(Score: 1.000)
Probably damaging
(Score: 1,037 my)
C.101G>A,  p.Cys34Tyr
(described in [18, 19])
Disease causing
(Score: 0.999999999)
Damaging
(Score: 0.02)
Deleterious
(Score: -5.971)
Most likely deleterious
(Class C65,  Score: 193.72)
Probably damaging
(Score: 1.000)
Probably damaging
(Score: 1,037 my)
(my: million years)
p.Cys34Ser (ACVRL1 Database in Mutation Databases 
of ARUP Laboratories,  Department of Pathology,  
University of Utah,  Salt Lake City,  UT,  http://arup.
utah.edu/database/ACVRL1/ACVRL1_display.php;  
accessed June 13,  2019).
Since 2000,  HHT diagnoses have generally been 
made based on Curaçao’s clinical diagnostic criteria.  
These criteria consist of four elements: (i) spontaneous 
and recurrent epistaxis; (ii) multiple telangiectasias at 
characteristic sites such as the lips,  oral cavity,  fingers,  
and nose; (iii) visceral AVM; and (iv) the presence of a 
first-degree relative with HHT based on these criteria.  
If 3 or 4 criteria are met,  the patient is diagnosed with 
“definite” HHT; if 2 criteria are met,  patients are con-
sidered to have “possible” HHT.  Patients meeting only 
one or none of the criteria are regarded as “unlikely” to 
have HHT [8].  As the present patient met two of the 
four criteria at his initial visit,  we made the diagnosis of 
possible HHT but not definite HHT.
Additionally,  the patient’s father was highly sus-
pected of having HHT due to his episodes of epistaxis 
and 2 instances of recalcitrant gastric bleeding.  
Although it appeared that the patient’s brother also 
potentially had HHT,  his clinical information did not 
meet the required diagnostic criteria.  If the patient’s 
father or brother were diagnosed with HHT,  our 
patient would be diagnosed as having definite HHT 
because the presence of a first-degree relative with HHT 
would be confirmed.  Our patient’s case was thus possi-
ble HHT and quite close to definite HHT.
Bossler et al.  described an HHT case with a 
c.101G>A,  p.Cys34Tyr mutation,  which was a mis-
sense mutation affecting the same amino acid residue 
[9].  They reported that the patient fulfilled all 4 ele-
ments of Curaçao’s criteria.  Al-Saleh et al.  also 
described a neonatal case of HHT with c.101G>A,  
p.Cys34Tyr mutation [10]; although the patient had no 
history of multiple telangiectasia or epistaxis,  he had a 
large AVM in the liver,  plus anemia.  That patient’s 
mother also exhibited the same mutation and had 
recurrent epistaxis,  cutaneous telangiectasia,  and pul-
monary AVM,  which met three of the 4 Curaçao crite-
ria.  The c.101G>A,  p.Cys34Tyr mutation is therefore 
definitely pathogenic.  Our in silico analysis using six 
software programs also showed high pathogenicity for 
p.Cys34Tyr and p.Cys34Ser mutations (Table 1).  Taking 
the past and present findings together,  it appears that 
the c.100T>A,  p.Cys34Ser mutation identified in our 
patient is highly pathogenic.
ACVRL1 (ALK1) protein is a serine-threonine 
kinase expressed mainly on the surface of endothelial 
cells.  It acts as a receptor for the TGF-β family of pro-
teins.  ACVRL1 includes 503 amino acids,  and the 
extracellular domain (residues 22-118) binds the bone 
morphogenetic proteins BMP9 and BMP10 [11].  Scotti 
et al.  performed a bioinformatics analysis using a struc-
tural model,  and they analyzed 29 known ACVRL1 
mutations in the extracellular domain.  Their results 
demonstrated that Cys34Tyr mutation has highly desta-
bilizing effects on the protein structure [12].  Ricard et 
al.  generated 19 ACVRL1 protein mutants,  including 3 
mutants of the extracellular domain (Cys51Tyr,  
Cys77Trp,  and Asn96Asp),  and transfected them into 
cells.  They found that all of the ACVRL1 mutants 
retained their ability to bind BMP9,  except for the 3 
mutants of the extracellular domain.  In addition,  the 
cells transfected with these 3 extracellular mutants had 
defective BMP9 signaling [13].  A functional analysis of 
the Cys34 residue has not been published,  but mutation 
of this residue may also induce a defect in BMP9 signal-
ing.
We have thus identified a novel c.100T>A,  
p.Cys34Ser mutation in ACVRL1.  It is likely that this 
mutation is pathogenic,  but there is a slight possibility 
that it is nonpathogenic.  Further investigations,  
including similar case reports,  will be needed to con-
firm our observation.
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